Introduction Accumulated high-quality data from randomised controlled trials (RCTs)
indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) …

Chronic obstructive pulmonary disease (COPD) can be prevented and treated through
effective care, reducing exacerbations and hospitalizations. Early identification of individuals …

Background COPD is a leading cause of death and disability. COPD therapy goals include
reducing exacerbations and improving symptom control. Single-inhaler triple therapy (SITT) …

Although pharmacological treatment of COPD is codified in different guidelines and strategy
documents, there is abundant evidence of discrepancy between what they suggest and what …

There are more single inhaler device triple therapy available for COPD patients now.
However, the effect of long-term triple therapy fixed dose combination (FDC) on mortality …

Acute exacerbations of COPD (ECOPD) are an important event in the life of a COPD patient
as it causes significant deterioration of physical, mental, and social health, hastens disease …

BACKGROUND: Clinical practice guidelines recommend dual long-acting muscarinic
antagonists (LAMAs)/long-acting β2agonists (LABAs) as maintenance therapy in patients …

Background: Some systematic reviews (SRs) on triple therapy (consisting of long-acting β2-
agonist, long-acting muscarinic antagonist, and inhaled corticosteroid, LABA/LAMA/ICS) for …

Background Randomized controlled trials described beneficial effects of inhaled triple
therapy (LABA/LAMA/ICS) in patients with chronic obstructive pulmonary disease (COPD) …

Background In the 52-week ETHOS study (NCT02465567), fixed-dose triple therapy with
budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) reduced moderate or …